Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen: http://doi.org/10.25358/openscience-8945
Autoren: Martin, Marcel
Ballal, Sanjana
Yadav, Madhav Prasad
Bal, Chandrasekhar
Van Rymenant, Yentl
De Loose, Joni
Verhulst, Emile
De Meester, Ingrid
Van Der Veken, Pieter
Roesch, Frank
Titel: Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics
Online-Publikationsdatum: 3-Apr-2023
Erscheinungsdatum: 2023
Sprache des Dokuments: Englisch
Zusammenfassung/Abstract: Radiopharmaceuticals based on the highly potent FAP inhibitor (FAPi) UAMC-1110 have shown great potential in molecular imaging, but the short tumor retention time of the monomers do not match the physical half-lives of the important therapeutic radionuclides 177Lu and 225Ac. This was improved with the dimer DOTAGA.(SA.FAPi)2, but pharmacological and radiolabeling properties still need optimization. Therefore, the novel FAPi homodimers DO3A.Glu.(FAPi)2 and DOTAGA.Glu.(FAPi)2. were synthesized and quantitatively radiolabeled with 68Ga, 90Y, 177Lu and 225Ac. The radiolabeled complexes showed high hydrophilicity and were generally stable in human serum (HS) and phosphate-buffered saline (PBS) at 37 °C over two half-lives, except for [225Ac]Ac-DOTAGA.Glu.(FAPi)2 in PBS. In vitro affinity studies resulted in subnanomolar IC50 values for FAP and high selectivity for FAP over the related proteases PREP and DPP4 for both compounds as well as for [natLu]Lu-DOTAGA.Glu.(FAPi)2. In a first proof-of-principle patient study (medullary thyroid cancer), [177Lu]Lu-DOTAGA.Glu.(FAPi)2 was compared to [177Lu]Lu-DOTAGA.(SA.FAPi)2. High uptake and long tumor retention was observed in both cases, but [177Lu]Lu-DOTAGA.Glu.(FAPi)2 significantly reduces uptake in non-target and critical organs (liver, colon). Overall, the novel FAPi homodimer DOTAGA.Glu.(FAPi)2 showed improved radiolabeling in vitro and pharmacological properties in vivo compared to DOTAGA.(SA.FAPi)2. [177Lu]Lu-DOTAGA.Glu.(FAPi)2 and [225Ac]Ac-DOTAGA.Glu.(FAPi)2 appear promising for translational application in patients.
DDC-Sachgruppe: 540 Chemie
540 Chemistry and allied sciences
Veröffentlichende Institution: Johannes Gutenberg-Universität Mainz
Organisationseinheit: FB 09 Chemie, Pharmazie u. Geowissensch.
Veröffentlichungsort: Mainz
ROR: https://ror.org/023b0x485
DOI: http://doi.org/10.25358/openscience-8945
Version: Published version
Publikationstyp: Zeitschriftenaufsatz
Weitere Angaben zur Dokumentart: Scientific article
Nutzungsrechte: CC BY
Informationen zu den Nutzungsrechten: https://creativecommons.org/licenses/by/4.0/
Zeitschrift: Cancers
15
6
Seitenzahl oder Artikelnummer: 1889
Verlag: MDPI
Verlagsort: Basel
Erscheinungsdatum: 2023
ISSN: 2072-6694
DOI der Originalveröffentlichung: 10.3390/cancers15061889
Enthalten in den Sammlungen:DFG-491381577-G

Dateien zu dieser Ressource:
  Datei Beschreibung GrößeFormat
Miniaturbild
novel_generation_of_fap_inhib-20230323150234702.pdfMartin, M. et al. Cancers 2023, 15(6), 1889.1.89 MBAdobe PDFÖffnen/Anzeigen
Miniaturbild
novel_generation_of_fap_inhib-20230323150602994.pdfMartin, M. et al. Cancers 2023, 15(6), 1889_Supplementary Information1.12 MBAdobe PDFÖffnen/Anzeigen